| **Accounts Receivable**                      | 9 Months Ended                                                                                                                                                                                                                                                                                                                                                  |
|----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
||
| **Notes to Financial Statements [Abstract]** |                                                                                                                                                                                                                                                                                                                                                            |
| Accounts Receivable                          | 5.  Accounts Receivable   September 30,2011  December 31,2010 Collaborators $709  $1,811 Royalties  1,240   - National Institutes of Health  538   468 Other  25   4 Total $2,512  $2,283  |

| X                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Details**Name:**pgnx_NotesToFinancialStatementsAbstract**Namespace Prefix:**pgnx**Data Type:**xbrli:stringItemType**Balance Type:**na**Period Type:**duration |
| X                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - Definition
Disclosure itemizing the various types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3, 4 -Article 5
+ Details**Name:**us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock**Namespace Prefix:**us-gaap**Data Type:**us-types:textBlockItemType**Balance Type:**na**Period Type:**duration |